Skip to content
Study details
Enrolling now

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Takeda
NCT IDNCT06095128ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

65

Study length

about 3.1 years

Ages

18–65

Locations

40 sites in AL, AZ, CA +19

About this study

Researchers are testing whether a treatment with vedolizumab and tofacitinib is effective for adults with ulcerative colitis. The trial also explores the effect of vedolizumab alone after this combined treatment.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Tofacitinib
  • 2.Take Vedolizumab
PhasePhase 4
DrugTofacitinib
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

tofacitinib, vedolizumab

Drug routes

oral (Oral Tablet), injection, intravenous

Endpoints

Secondary: Change in C-Reactive Protein Levels (CRP) From Baseline, Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline, Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)

Body systems

Gastroenterology